Assessing the Effect of Shatavari Supplementation on Bone and Skeletal Muscle Health in Healthy Postmenopausal Women
Study Details
Study Description
Brief Summary
Shatavari is a plant that grows in Nepal, Sri Lanka, India and the Himalayas and its root has long been used in Ayurvedic medicine. Its traditional uses include supporting women's health, particularly during breastfeeding and during the perimenopausal period. Shatavari has been found to contain substances that have similar chemical properties to estrogen. A decrease in the amount of ovarian estrogen production causes the menopause and this reduction in circulating estrogen has widespread effects, including promoting a decrease in bone density. This increases the risk of bone fractures. Having less oestrogen is also thought to contribute to a loss of muscle strength in postmenopausal women.
As shatavari may act on the body's tissues in a similar way to estrogen, shatavari supplementation may represent one way of preventing postmenopausal bone and muscle loss. This study will investigate these questions. 24 healthy postmenopausal women aged 60 years or older will be recruited. The participants will be randomly assigned to consume shatavari (1000 mg per day, equivalent to 26,500 mg per day fresh weight shatavari) or placebo (1000 mg per day magnesium stearate) for 6 weeks. Handgrip and knee extensor strength will be measured at baseline and at 6 weeks. Vastus lateralis (VL) muscle biopsy samples will be obtained at baseline and at 6 weeks and analysed for markers of muscle function and protein turnover. Plasma and serum samples will be collected via venepuncture and markers of bone turnover (P1NP, β-CTX) will be measured at baseline and at 6 weeks. Primary human osteoblasts (not obtained from these participants) will be stimulated with pooled sera from the placebo and shatavari supplementation conditions to assess markers of osteoblast (bone-building) activity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Shatavari 1000 mg per day shatavari root powder (2 x 500 mg opaque capsules; equivalent to 26,500 mg fresh weight shatavari). Ingested in the morning, daily for 6 weeks. |
Dietary Supplement: Shatavari
Shatavari root powder
Other Names:
|
| Placebo Comparator: Placebo 1000 mg per day magnesium stearate powder (2 x 500 mg opaque capsules). Ingested in the morning, daily for 6 weeks. |
Dietary Supplement: Magnesium stearate
Magnesium stearate powder
|
Outcome Measures
Primary Outcome Measures
- Change in protein expression of myogenin in vastus lateralis skeletal muscle samples. [Change from baseline myogenin expression at 6 weeks.]
Measured via immunoblotting.
Secondary Outcome Measures
- Change in plasma concentration of markers of bone turnover. [Change from baseline concentration at 6 weeks.]
P1NP and β-CTX.
- Change in plasma concentration of markers of inflammation. [Change from baseline concentration at 6 weeks.]
C-reactive protein and IL-6.
- Change in handgrip strength. [Change from baseline strength at 6 weeks.]
Assessed using a handgrip dynamometer, measured in kilograms.
- Change in isometric knee extensor strength [Change from baseline strength at 6 weeks.]
Assesed using an isokinetic dynamometer, measured in Newtons.
- Change in isokinetc knee extensor strength [Change from baseline strength at 6 weeks.]
Assesed using an isokinetic dynamometer, measured in Newtons.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Postmenopausal women (Last menstrual period > 12 months ago)
-
Aged 60 years or older
Exclusion Criteria:
-
BMI ≥ 30
-
Diagnosis (DEXA t-score < -2.5) and/or treatment for the prevention of osteoporosis, including treatmeat with bisphosphonates and non-bisphosphonates (including, but not limited to raloxifene, denosumab, teriparatide, calcitriol and estrogenic hormone replacement therapy).
-
Currently taking estrogenic hormone replacement therapy or history of estrogenic hormone replacement therapy in the past 5 years via any route of administration apart from vaginal.
-
PAR-Q+ screening indicates physical activity is unsuitable.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Deparment of Sport and Health Sciences | Exeter | Devon | United Kingdom | EX12LU |
Sponsors and Collaborators
- University of Exeter
Investigators
- Principal Investigator: Mary O'Leary, University of Exeter
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 190206/B/01